On May 27, 2026, the Reagan-Udall Foundation for the FDA, working alongside ARPA-H and the XPRIZE Foundation, ran a full-day public meeting on gerotherapeutic drug and biologic development. Strip away the dense regulatory jargon, and it was the exact conversation the longevity industry has needed for years: a direct discussion between developers and regulators on how to translate geroscience into approvable human clinical trials.